<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116145">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110368</url>
  </required_header>
  <id_info>
    <org_study_id>AL1401</org_study_id>
    <nct_id>NCT02110368</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions</brief_title>
  <official_title>An Open-Label, Randomized, Balanced, Single-Dose, Two Treatment, Four Period, Two Sequence Replicate Design, Bioequivalence Study Of Testosterone Topical Gel, 1.62% Metered Pump, Manufactured By Amneal Pharmaceuticals LLC With AndroGel (Testosterone Gel) 1.62% Metered-Dose Pump, Marketed By Abbvie Inc., In Testosterone-Deficient (Hypogonadal) Adult Male Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amneal Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Phase One Solutions, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amneal Pharmaceuticals, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study comparing the rate and extent of testosterone absorption for a test
      formulation versus the reference product.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the rate and extent of testosterone absorption for a test formulation of
      Testosterone Topical Gel, 1.62% Metered Pump, manufactured  with that of AndroGel速
      (testosterone gel) 1.62% Metered-Dose Pump, in normal, healthy, adult,
      testosterone-deficient (hypogonadal) human male subjects  under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration vs. time curve, from the time of first dosing to the time of the last measured concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration vs. time curve, from time of first dosing to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum reported concentration. Estimated for both baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time at which Cmax is first observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apparent first order terminal elimination rate constant determined from the terminal log-linear concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T 1/2</measure>
    <time_frame>Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Primary Hypogonadism</condition>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>AndroGel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Topical Gel, 1.62% Metered Pump</intervention_name>
    <arm_group_label>Testosterone Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel (testosterone gel) 1.62% Metered-Dose Pump</intervention_name>
    <arm_group_label>AndroGel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men with hypogonadism with testosterone levels &lt;250ng/dL

          -  18 to 65 years of age (inclusive)

          -  Have normal PSA &lt; 4.0ng/mL

          -  Weighing a minimum of 50 kg and having a body mass index between 18.0 and 38.0 kg/m2.

          -  Good health as determined by medical history and lack of clinically significant
             abnormalities (other than hypogonadism).

          -  Vital signs,  must be within the following ranges  heart rate: 45-100 bpm; systolic
             BP: 90-150 mmHg; diastolic BP: 50-90 mmHg. Out-of-range vital signs may be repeated.

        Exclusion Criteria:

          -  Is female

          -  History of allergy or sensitivity to AndroGel速 or any component of drug or a related
             testosterone drug, Axiron速, Testim速, etc.

          -  History of allergy or intolerance to soy, soybean, and/or soy lecithin

          -  History of any drug or food hypersensitivity or intolerance which, would compromise
             the safety of the subject or the study.

          -  History or presence of clinically significant ocular, cardiovascular, pulmonary,
             hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, oncologic, or psychiatric disease or any othercondition that, would
             jeopardize the safety of the subject or the validity of the study results.

          -  Had no major surgery or illness within 3 months before screening.

          -  History or presence of benign prostate hypertrophy, prostate and/or breast cancer.

          -  Has tattooed, damaged, scarred skin or any skin condition on right or left upper arm
             and shoulder region that may affect absorption of drug.

          -  Has a clinically significant abnormal finding on the physical exam, medical history,
             electrocardiogram or clinical laboratory results at screening.

          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose
             of study medication.

          -  Has donated blood within 56 days or plasma within 30 days prior to the first dose of
             study medication.

          -  Has participated in another clinical trial within 30 days prior to the first dose of
             study medication.

          -  Has used any over-the-counter  medication, including nutritional supplements, within
             7 days prior to the first dose of study medication.

          -  Has used any prescription medication including hormonal treatment and or supplement
             within 30 days prior to the first dose of study medication.

          -  No depot injections or drug implants within 3 months of first dose of study
             medication.

          -  Has been treated with any known drugs that are moderate or strong inhibitors/inducers
             of CYP enzymes such as barbiturates, phenothiazine, cimetidine, carbamazepine, etc.,
             within 30 days prior to the first dose of study medication and that may impact
             subject safety or the validity of the study results.

          -  Has positive cotinine test and/or smoked or used tobacco products within 60 days
             prior to the first dose of study medication

          -  Has a positive urine screen for drugs of abuse

          -  Has positive alcohol breathalyzer test

          -  Has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, or Human
             Immunodeficiency Virus (HIV) at screening or has been previously treated for
             Hepatitis B, Hepatitis C, or HIV infection.

          -  Any difficulty fasting or has any dietary restrictions such as lactose intolerance,
             vegan, low-fat, etc.

          -  Unavailable for any confinement days or scheduled visits.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Galitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phae 1 Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase One Solutions, Inc.</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
